How much funding has MedAnnex raised?

MedAnnex has raised $13.8M in total funding, most recently a Series B round.

Who are MedAnnex's investors?

MedAnnex's investors include Morningside Group, Scottish Investment Bank.

Where is MedAnnex headquartered?

MedAnnex is headquartered in Edinburgh, United Kingdom.

MedAnnex

Edinburgh, United Kingdom · Founded 2009 · $13.8M raised

Biotech

Headquarters: Edinburgh
Employees: 11–50
Founded: 2009
Business Model: B2B

Website: medannex.org
Total Funding: $13.8M
Last Round: $13.8M Series BAug 2019
Rounds: 1

About

Medannex is pioneering the targeting of annexin-A1 to provide powerful new treatment options for people impacted by cancers and autoimmune diseases. Annexin-A1 drives cancer cell growth and migration and also plays a key role in the development of several autoimmune conditions. Extensive pre-clinical data demonstrate that its first-in-class monoclonal antibody therapeutic (MDX-124) effectively blocks the action of annexin-A1, and a Phase 1b clinical study is under way in cancer patients, with further autoimmune studies in preparation.

Summary

MedAnnex is a Biotech company based in Edinburgh, United Kingdom, founded in 2009. It has raised $13.8M in total across 1 round, most recently a $13.8M Series B round in Aug 2019. Investors include Morningside Group and Scottish Investment Bank.